Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
We report the first highly selective kinetic resolution of racemic α-chiral azides by Cu-catalyzed azide-alkyne cycloadditions (CuAAC), providing facile access to chiral α-tertiary azides and 1,2,3-triazoles with newly developed PYBOX ligands with a C4 sulfonyl group. The key role of the C4 sulfonyl in tuning the electronic and steric properties of the chiral catalysts to enhance enantiomer discrimination
A novel class of C2-symmetric ligand has been prepared using an intramolecular cyclisation reaction of a diazaphosphole borane complex. Preliminary results of its application to the asymmetriccatalysis of hydrogenation, hydrosilylation and allylic substitution reactions are described.